MedTrace Logo

VENICE Study Nevirapine Full Dose/Dose Escalation

NCT00704249 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-02-11

No results posted yet for this study

Summary

This study aims to compare the trough plasma concentrations of nevirapine after 7 days of treatment at the full dose from baseline with dose escalation in patients taking efavirenz who switch to nevirapine due to neuropsychiatric adverse reactions.

Conditions

  • HIV Infections

Interventions

DRUG

nevirapine

Full-dose nevirapine from baseline (200 mg bid).

DRUG

nevirapine

Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)

Sponsors & Collaborators

  • Clinical Trial Agency of HIV Study Group

    lead OTHER

Principal Investigators

  • Esteban Ribera · Clinical Trial Agency of HIV Study Group

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-07-31
Completion
2009-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00704249 on ClinicalTrials.gov